Prosecution Insights
Last updated: April 19, 2026
Application No. 18/274,711

METHOD FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE

Non-Final OA §112
Filed
Jul 27, 2023
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tagcyx Biotechnologies Inc.
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
88%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
553 granted / 740 resolved
+14.7% vs TC avg
Moderate +14% lift
Without
With
+13.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
52 currently pending
Career history
792
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
27.5%
-12.5% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 740 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAIL ACTION This office action is a response to a 371 application filed 7/27/2023, which is a national stage application of PCT/JP2022/003130 filed 1/27/2022, which claims foreign priority to JP2021-013677 filed 1/29/2021. As filed, claims 1-3 are pending. Information Disclosure Statement The information disclosure statement (IDS) submitted on 7/27/2023 and 4/10/2025 has been considered by the Examiner. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim recites the phrase, “a compound having a 5-X-2-thienyl group”. Suzuki-Miyaura coupling reaction conditions require the abovementioned compound to have an organoboron group, and the transitional phrase, “having”, could be interpreted as either open- or close-ended, according to the guidance in MPEP 2111.03(IV). However, the word, “compound”, is singular and requires a definite chemical formula, and therefore, “having”, cannot be interpreted as open-ended. Therefore, it is unclear to the Examiner how the abovementioned compound can undergo Suzuki-Miyaura coupling reaction without having an organoboron group. The metes and bounds of this claim is unclear, which rendered the claim indefinite. Regarding claim 1, the claim is drawn to a method of making a compound of instant formula (I). However, the claim only recites the reaction step for making 2-amino-3-nitro-4-(5-X-2-thienyl)pyridine. Therefore, it is unclear to the Examiner how the compound of instant formula (I) can be made from 2-amino-3-nitro-4-(5-X-2-thienyl)pyridine. The metes and bounds of this claim is unclear, which rendered the claim indefinite. Regarding claims 2 and 3, the claims are dependent of claim 1, and they failed to correct the indefiniteness issue of claim 1, which rendered these claims indefinite. Conclusion Claims 1-3 are rejected. The instant claims are drawn to a method of making a compound of instant formula (I); and the use of Suzuki-Miyaura coupling reaction does not appear to have been disclosed previously in the prior arts. For at least this reason, the instant claims are substantially differentiated from any prior art reference, such as U.S. Patent Application Publication No. 2008/0125381, hereinafter Hirao (see IDS filed 7/27/2023). Furthermore, the prior art provide insufficient guidance or motivation that would have led a person having ordinary skill in the art to arrive at the instantly claimed process. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jul 27, 2023
Application Filed
Oct 30, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595225
METHOD FOR PRODUCING ASYMMETRIC LINEAR CARBONATE
2y 5m to grant Granted Apr 07, 2026
Patent 12582632
INHIBITION OF NEUROLOGICAL INJURIES DUE TO INFECTIONS VIA ADMINISTRATION OF BUTANETAP AND ANALOGS THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12571801
Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging
2y 5m to grant Granted Mar 10, 2026
Patent 12552792
SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME
2y 5m to grant Granted Feb 17, 2026
Patent 12552782
Analogs of Nitrofuran Antibiotics to Combat Resistance
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
88%
With Interview (+13.8%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 740 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month